Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease

Journal of Hepatology

Volumn 51, Issue 5, 2009, Pages 931-938

  Papatheodoridis, George V ^a   Chrysanthos, Nikolaos ^a   Cholongitas, Evangelos ^a   Pavlou, Efthymia ^b   Apergis, George ^b   Tiniakos, Dina G ^a   Andrioti, Evangelia ^b   Theodossiades, George ^b   Archimandritis, Athanasios J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Anticardiolipin antibodies; Antithrombin III; Liver fibrosis; Non alcoholic fatty liver disease; Plasminogen; Protein C; Protein S; Steatohepatitis; Thrombotic risk factor

Indexed keywords

ANTITHROMBIN III; CARDIOLIPIN ANTIBODY; PLASMINOGEN; PROTEIN C; PROTEIN S;

ADULT; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; COHORT STUDIES; FACTOR V; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROTHROMBIN; RISK FACTORS; THROMBOSIS;

EID: 70349732866     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.06.023     Document Type: Article

References (29)

1. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 1705-1725
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
3. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2 (2004) 1048-1056
4. Bergman R.N. New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res 52 (1997) 359-385
5. Friedman S.L., Maher J.J., and Bissell D.M. Mechanisms and therapy of hepatic fibrosis: report of the AASLD single topic basic research conference. Hepatology 32 (2000) 1403-1408
6. Wanless I.R., Wong F., Blendis L.M., Greig P., Heathcote E.J., and Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 21 (1995) 1238-1247
7. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 353 (1999) 1167-1173
8. Papatheodoridis G.V., Papakonstantinou E., Andrioti E., Cholongitas E., Petraki K., and Hadziyannis S.J. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 52 (2003) 404-409
9. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003) 518-526
10. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: a noninvasive system that indentifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007) 846-854
11. Papatheodoridis G.V., and Burroughs A.K. Hemostasis in hepatic and biliary disorders. In: Blumgart L.H., and Fong Y. (Eds). Surgery of the liver and biliary tract (2000), W.B. Saunders, London 199-213
12. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., and Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474
13. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
14. Targher G., Chonchol M., Miele L., Zoppini G., Pichiri I., and Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 35 (2009) 277-287
15. Northup P.G., Sundaram V., Fallon M.B., Reddy K.R., Balogun R.A., Sanyal A.J., et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 6 (2008) 2-9
16. Yener S., Akarsu M., Demir T., Akinci B., Sagol O., Bayraktar F., et al. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis. J Endocrinol Invest 30 (2007) 810-819
17. Assy N., Bekirov I., Mejritsky Y., Solomon L., Szvalb S., and Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 11 (2005) 5834-5839
18. Goodman Z.D., and Ishak K.G. Occlusive venous lesions in alcoholic liver disease: a study of 200 cases. Gastroenterology 83 (1982) 786-796
19. Nakanuma Y., Ohta G., and Doishita K. Quantitation and serial section observations of focal veno-occlusive lesions of hepatic veins in liver cirrhosis. Virchows Arch 405 (1985) 429-438
20. Anstee Q.M., Wright M., Goldin R., and Thursz M.R. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis 13 (2009) 117-126
21. Wanless I.R., and Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 24 (2004) 99-106
22. Wanless I.R., Belgiorno J., and Huet P.M. Hepatic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit: 1. Morphology and inhibition of fibrogenesis by dipyridamole. Hepatology 24 (1996) 855-864
23. Anstee Q.M., Goldin R.D., Wright M., Martinelli A., Cox R., and Thursz M.R. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 6 (2008) 1336-1343
24. Assy N., Hussein O., Khalil A., Luder A., Szvalb S., Paizi M., et al. The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci 52 (2007) 1187-1193
25. Marra F., Grandaliano G., Valente A.J., and Abboud H.E. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 22 (1995) 780-787
26. Marra F., DeFranco R., Grappone C., Milani S., Pinzani M., Pellegrini G., et al. Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology 27 (1998) 462-471
27. Uthman I.W., and Gharavi A.E. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 31 (2002) 256-263
28. Ordi-Ros J., Villarreal J., Monegal F., Sauleda S., Esteban I., and Vilardell M. Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome. Clin Diagn Lab Immunol 7 (2000) 241-244
29. Vay D., Rigamonti C., Vidali M., Mottaran E., Alchera E., Occhino G., et al. Anti-phospholipid antibodies associated with alcoholic liver disease target oxidized phosphatidylserine on apoptotic cell plasma membranes. J Hepatol 44 (2006) 183-189